# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage radiopharmaceutical company focused on developing innovative treatmen...
Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage radiopharmaceutical company focused on developing innovative treatmen...
HC Wainwright & Co. analyst Sean Lee reiterates Monopar Therapeutics (NASDAQ:MNPR) with a Buy and maintains $2 price tar...
Monopar Therapeutics (NASDAQ:MNPR) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of ...